CIK 0001048477
- Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 680397820
- Phone
- +1 415-506-6700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,163,748
- in 1 filing
Net −$1,163,748. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-09 | BIENAIME JEAN JACQUES Director | Sale 10b5-1 | −10,000 | $98.19 | $982K | 425,162 |
| 2024-01-09 | BIENAIME JEAN JACQUES Director | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −10,000 | 171,000 | ||
| 2024-01-08 | MEIER RICHARD A Director | Gift | −3,000 | 112,547 | ||
| 2024-01-08 | BIENAIME JEAN JACQUES Director | Other acquisition 10b5-1 | +50 | $99.05 | $5K | 425,162 |
| 2023-12-27 | Bodem Barbara W. Director | Grant or award | +2,180 | 2,180 | ||
| 2023-12-27 | Enyedy Mark J Director | Grant or award | +2,180 | 2,180 | ||
| 2023-12-27 | Countouriotis Athena Director | Grant or award | +2,180 | 2,180 | ||
| 2023-12-21 | BIENAIME JEAN JACQUES Director | Exercise or conversion 10b5-1 | +10,000 | $63.10 | $631K | 435,112 |
| 2023-12-21 | BIENAIME JEAN JACQUES Director | Sale 10b5-1 | −10,000 | $93.99 | $940K | 425,112 |
| 2023-12-21 | BIENAIME JEAN JACQUES Director | Exercise or conversion · Stock Option (Right to Buy Common Stock) 10b5-1 | −10,000 | 181,000 | ||
| 2023-12-13 | Davis George Eric EVP, Chief Legal Officer | Sale 10b5-1 | −13,764 | $95.30 | $1.3M | 55,710 |
| 2023-12-01 | BIENAIME JEAN JACQUES Director | Grant or award | +2,370 | 425,112 | ||
| 2023-12-01 | Hardy Alexander Chief Executive Officer | Grant or award | +68,039 | 68,039 | ||
| 2023-12-01 | Hardy Alexander Chief Executive Officer | Grant or award | +47,332 | 115,371 | ||
| 2023-12-01 | Hardy Alexander Chief Executive Officer | Grant or award · Stock Option (Right to Buy Common Stock) | +150,529 | 150,529 | ||
| 2023-12-01 | Guyer Charles Greg EVP, Chief Technical Officer | Grant or award | +11,840 | 52,014 | ||
| 2023-12-01 | FUCHS HENRY J President, Worldwide R&D | Grant or award | +17,750 | 194,254 | ||
| 2023-10-31 | Guyer Charles Greg EVP, Chief Technical Officer | Grant or award | +133 | $69.23 | $9K | 40,174 |
| 2023-10-04 | BIENAIME JEAN JACQUES Director | Other acquisition | +10 | $85.57 | $856 | 422,742 |
| 2023-08-16 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale 10b5-1 | −5,000 | $90.00 | $450K | 60,804 |
Page 12 of 23 · 450 trades